Chevron Corp vs Medpace Holdings Inc — how do they compare? Chevron Corp trades at $196.7 (market cap $385.77B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Chevron Corp is far larger — about 22.8× Medpace Holdings Inc's market cap, and Chevron Corp pays a 3.62% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| CVX | MEDP | |
|---|---|---|
Market Cap | $385.77B | $16.90B |
Volume | 9,807,834 | — |
Sector | Energy | Technology |
52-Week High | $211.14 | $620.59 |
52-Week Low | $146.72 | $393.42 |
Enterprise Value | $414.31B | $16.52B |
Dividend Yield | 3.62% | — |
Signals from Pluang's Aura AI — not financial advice
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →